May 4-7, 2017

Omniox will present at the 5th Quadrennial World Federation of Neuro-Oncology Societies Meeting in Zurich, Switzerland

Dr. Le Moan, Director of Translational Research, will present: “By reversing tumor hypoxia, OMX, an IND-stage drug candidate, promotes anti-tumor response and increases survival in the GL261 intracranial glioblastoma model” (Abstract A-177).

April 3 and 4, 2017

Omniox presented two posters at the American Association for Cancer Research Annual Meeting in Washington, D.C.

Dr. Leong, Director of Oncology Research, and Dr. Pan, Scientist in the Oncology Group, presented preclinical data in subcutaneous syngeneic mouse tumor models demonstrating that by oxygenating hypoxic tumor tissue, OMX-4.80P induces a microenvironmental change from an immunosuppressive to an immunopermissive state. When administered alone or combined with checkpoint inhibitors, OMX-4.80P increased anti-tumor activity, even in tumor models that are non-responsive to checkpoint inhibitors.

Dr. Le Moan, Director of Translational Research, presented the therapeutic potential of OMX-4.80P for glioblastoma, demonstrating OMX-4.80P oxygenates and immunosensitizes orthotopic glioblastoma mouse tumors, promotes survival and tumor control as a monotherapy, and increases checkpoint inhibitor efficacy in established tumors.

Tuesday, 21 March 2017

Omniox presented a poster at the Keystone Cancer Immunology and Immunotherapy Oncology Conference in Whistler, British Columbia, Canada

Dr. Le Moan, Director of Translational Research, presented preclinical data showing that OMX-4.80P restores anti-tumor immunity and, when combined with checkpoint inhibitors, improves anti-tumor efficacy in orthotopic and subcutaneous mouse tumor models.

Thursday, 9 March 2017

Omniox’s UCSF collaborators presented a podium talk at the Keystone Adaptations to Hypoxia in Physiology and Disease Conference in Whistler, British Columbia, Canada

UCSF collaborator and neonatal intensivist, Dr. Jason Boehme, MD from Dr. Emin Maltepe’s group, presented data demonstrating the protective effect of an OMX variant on myocardial function in an acute hypoxia lamb model. These data were acquired as part of collaboration with UCSF critical care investigators, Drs. Maltepe, MD and Jeffrey Fineman, MD.

Friday, 13 January 2017

Omniox publishes its first book chapter on oxygenating ischemic brain tissue after stroke to preserve the neurovascular unit

Dr. Le Moan, Director of Translational Research, was invited to publish a book chapter in “Neuroprotective Therapy for Stroke and Ischemic Disease” (edited by Paul A. Lapchak and John H. Zhang, experts in the field of stroke) discussing the promising use of adjunctive therapies to enhance the benefits of recanalization after stroke. In particular, the chapter focuses on the concept of oxygen therapy and oxygen carriers, highlighting advantages of the H-NOX technology, as a valid approach to protect hypoxic brain tissue until clot removal.

November 17 and 18, 2016

Omniox presents preclinical data on immuno-sensitizing effects of OMX-4.80P in orthotopic glioblastoma tumors at the CNS Anti-Cancer Drug Discovery Conference and 21st Annual Society for Neuro-Oncology Meeting in Scottsdale, Arizona

Dr. Krtolica, VP of Research and Dr. Le Moan, Director of Translational Research, presented a podium talk and a poster showing OMX-4.80P acts as a broad modulator of the hypoxic tumor microenvironment and enhances the efficacy of PD1-targeted therapy in orthotopic glioblastoma. Given its multi-pronged immuno-sensitizing activity and good tolerability, OMX-4.80P holds the potential to synergize with radiotherapy and multiple immunotherapeutic agents to enhance tumor control and improve patient outcomes in glioblastoma.

Monday, 26 September 2016

Omniox presents preclinical data on OMX-4.80P’s immunostimulatory effects in hypoxic tumors at the CTI-CIMT-EATI-AACR 2nd International Cancer Immunotherapy Conference in New York, NY

Dr. Krtolica, VP of Research, presented Omniox’s preclinical data in multiple syngeneic tumor models demonstrating OMX-4.80P alone can relieve hypoxia-driven immunosuppression and may enhance survival when used in combination with a checkpoint inhibitor.

Wednesday, 20 April 2016

Omniox presents preclinical data on OMX-4.80P as a cancer immunotherapy at
the 2016 Annual Meeting of the American Association for Cancer Research in New Orleans, LA

Dr. Krtolica, VP of Research, presented Omniox’ preclinical data in several mouse cancer models demonstrating that OMX-4.80P affects multiple immunosuppressive pathways in tumors to enhance T cell infiltration.

Friday, 19 February 2016

Omniox presents preclinical efficacy data in focal brain ischemia at the 2016 Annual International Stroke Conference in Los Angeles, CA

Dr. Le Moan, Director of Translational Research, presented the therapeutic potential of Omniox’ OMX-IS product candidate for stroke, to be used in combination with reperfusion therapies to preserve brain cells and improve neurological function and long-term patient outcomes.

Sunday, 22 November 2015

Omniox presents podium talk and poster at the 20th Annual Scientific Meeting of the Society for Neuro-Oncology in San Antonio

Dr. Krtolica, VP of Research, presented data on real-time PET imaging performed in collaboration with UCSF. Dr. Leung presented results from a clinical trial of OMX-4.80P in canine brain cancer conducted in collaboration with Professor Michael Kent at UC Davis.

Wednesday, 21 October 2015

Omniox presents at the 2015 Society for Neuroscience Conference

Dr. Le Moan and Dr. Leung presented preclinical stroke data demonstrating Omniox’ stroke drug candidate can be used to stabilize at-risk brain tissue to ultimately improve clinical outcomes in stroke patients.

Thursday, 09 October 2014

Omniox, Inc. Receives Wellcome Trust Translation Fund Award

Omniox receives a $5.8 million translational award to support bringing our lead product to clinical trials.

Tuesday, 16 April 2013

The QB3 Bridging-The-Gap Awards: A Story Of Success

Omniox receives a $3 million NCI SBIR Phase II Bridge Award.

Tuesday, 23 November 2010

The Key Ingredient to Effective Cancer Treatments

Omniox receives a $3 million SBIR Phase II grant from the National Cancer Institute.

Tuesday, 01 December 2009

Omniox receives an SBIR Phase I grant from the National Cancer Institute

Omniox receives $500,000 to develop our lead product as a treatment for cancer.